Glenmark Pharmaceuticals Ltd The group is active in new product launches and regulatory approvals in the U.S. and Europe

$GLENMARK recent items include U.S. launches (various injectables and generics), a U.S. FDA approval for a progesterone vaginal insert, and the launch of Winlevi® (clascoterone) in key European ***** has moved to directly commercialize Ryaltris® in the U.S., signalling a strategic shift to more direct distribution for select innovative products in that market.